Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") |
m (→Chemotherapy) |
||
| Line 22: | Line 22: | ||
*Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy | *Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy | ||
*Biomarker exclusions: EGFR exon 20 [[Biomarkers#SNV|mutations]] | *Biomarker exclusions: EGFR exon 20 [[Biomarkers#SNV|mutations]] | ||
| − | ==== | + | ====Targeted therapy==== |
*[[Erlotinib (Tarceva)]] 150 mg PO once per day | *[[Erlotinib (Tarceva)]] 150 mg PO once per day | ||
Revision as of 16:09, 27 August 2020
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hainsworth et al. 2018 (MyPathway) | Phase IIa, <20 pts in this arm |
Biomarker eligibility criteria
- Gene: EGFR
- Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
- Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
- Biomarker exclusions: EGFR exon 20 mutations
Targeted therapy
- Erlotinib (Tarceva) 150 mg PO once per day
Continued indefinitely
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed